Physician profile
Maninder Kohli
NPI 1851390348
$4,479.33
in general payments reported to CMS, 2019-2025
29 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $1,281 · 2021: $737 · 2023: $575 · 2024: $456 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $513.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $474.14 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $368.45 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $345.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $341.09 | 2019-2021 | |
| Lilly USA, LLC | $321.62 | 2019-2024 | Zepbound |
| Abbvie INC. | $314.66 | 2021-2023 | |
| Edwards Lifesciences Corporation | $268.01 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Phathom Pharmaceuticals, INC. | $237.61 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $206.85 | 2020-2023 | Verquvo |
| Sunovion Pharmaceuticals INC. | $162.62 | 2019-2020 | |
| Pfizer INC. | $156.21 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.20 | 2020-2025 | Jardiance |
| Amarin Pharma, INC. | $136.98 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.55 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $70.94 | 2019-2021 | |
| Esperion Therapeutics, INC. | $65.35 | 2020-2021 | |
| Horizon Therapeutics Plc | $36.02 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $34.22 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.74 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.40 | 2020-2021 | |
| Exact Sciences Corporation | $28.58 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $18.23 | 2020 | |
| Ibsa Pharma INC. | $18.14 | 2021 | |
| Medtronic Minimed, INC. | $17.16 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.12 | 2020 | |
| Hikma Pharmaceuticals USA | $13.53 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.53 | 2021 | |
| Medtronic Vascular, INC. | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maninder Kohli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.